Moreover, although in our knowledge FXa inhibitors as rivaroxaban have not been used as therapeutic alternative to prevent coagulopathies induced by COVID-19, it probably has a place for the treatment of hospitalized COVID-19 patients with low bleeding risk, particularly considering other reported properties of rivaroxaban such as its anti-inflammatory, antioxidant properties, and now probably its ability to protect mitochondria of HPMEC from the COVID-19 spike subunits. This evidence concerns the gene F10 and blood coagulation disease.